Medicinal composition containing levodopa and benserazide hydrochloride

A technology of benserazide hydrochloride and levodopa, which is applied to the pharmaceutical composition of symptomatic Parkinson's syndrome, and the field of treating Parkinson's disease, can solve the problem of color change, benserazide hydrochloride light and wet instability, and difficult finished product quality. control issues

Active Publication Date: 2010-01-13
AVENTIS PHARMA HAINAN
View PDF3 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, benserazide hydrochloride is unstable to light and humidity, not only the color will change, but the related substances will also increase significantly. When the two are used in combination and mixed directly, they will also interact. Even if the storage conditions are strictly required, The quality of the finished product is also difficult to control

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition containing levodopa and benserazide hydrochloride
  • Medicinal composition containing levodopa and benserazide hydrochloride
  • Medicinal composition containing levodopa and benserazide hydrochloride

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016]

[0017] Preparation:

[0018] The prescription amount of benserazide hydrochloride is weighed, placed in the ethanol solution of povidone, and spray-dried to obtain the carrier substance of benserazide hydrochloride. Mix the carrier substance of benserazide hydrochloride and other auxiliary materials evenly, put it into a tablet machine, and press it into tablets to obtain the product.

Embodiment 2

[0020]

[0021] Preparation:

[0022] Weighing a prescribed amount of benserazide hydrochloride, placing it in an aqueous solution of hydroxypropyl β-cyclodextrin, and spray-drying to obtain a carrier substance of benserazide hydrochloride. Mix the carrier substance of benserazide hydrochloride and other auxiliary materials evenly, put it into a tablet machine, and press it into tablets to obtain the product.

Embodiment 3

[0024]

[0025] Preparation:

[0026] Weighing the prescribed amount of benserazide hydrochloride, placing it in ethanol solution of hydroxyethyl methylcellulose, and spray drying to obtain the carrier substance of benserazide hydrochloride. Mix the carrier substance of benserazide hydrochloride and other auxiliary materials evenly, put it into a tablet machine, and press it into tablets to obtain the product.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a medicinal composition containing levodopa and benserazide hydrochloride, which is formed by dispersing the benserazide hydrochloride in a specific carrier and then mixing the carrier with the levodopa and a pharmaceutically acceptable carrier. The composition has good stability and is used for treating parkinsonism and symptomatic Parkinson syndrome (postencephalitic, arteriosclerotic or toxic).

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating Parkinson's disease and symptomatic Parkinson's syndrome, in particular to a solid pharmaceutical composition containing levodopa and benserazide hydrochloride. Background technique [0002] Parkinson's disease is a chronic disease with a high incidence rate at present. Dopamine deficiency in the basal ganglia of Parkinson's disease patients. Unlike dopamine, levodopa can cross the blood-brain barrier and enter the central nervous system. As a direct metabolic precursor of dopamine, it makes dopamine replacement therapy feasible. However, levodopa is rapidly decarboxylated outside the brain and transformed into dopamine, which leads to a large amount of waste of levodopa and frequent occurrence of adverse reactions. Therefore, it would be beneficial to inhibit the extracerebral decarboxylation of levodopa. This is achieved by co-administering levodopa and an extracerebral decarboxyla...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/198A61K31/16A61K9/00A61P25/16
Inventor 袁筝
Owner AVENTIS PHARMA HAINAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap